Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

Treatment A-Bemnifosbuvir/Ruzasvir FDC

Small molecule · developed by Atea Pharmaceuticals

Phase 1 Most advanced trial (none active)

AVIR Developer

1 Registered trials

What is Treatment A-Bemnifosbuvir/Ruzasvir FDC?

Bemnifosbuvir/ruzasvir is a fixed-dose combination tablet (275 mg/90 mg per tablet) studied as a single 550 mg/180 mg dose under fasting conditions in a healthy volunteer study.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type: Small molecule
Developer: Atea Pharmaceuticals, Inc. (AVIR)
FDA status: Investigational, not approved in the US. Most advanced trial: Phase 1

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT07007806	Phase 1	Healthy Volunteer Study	Completed	AVIR

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Healthy Volunteer Study

More from Atea Pharmaceuticals

AT-527 Phase 1 AT-587 Phase 1 AT-752 Phase 2 AT-777 Phase 1/2 Bemnifosbuvir Phase 3 Bemnifosbuvir-Ruzasvir Phase 3 Ethinyl Estradioll/Levonorgestrel Phase 1 Ruzasvir Phase 2

Sources

ClinicalTrials.gov NCT07007806

Updated Oct 11, 2026. Something wrong or missing? Report it on the AVIR page.

Follow AVIR, the company behind Treatment A-Bemnifosbuvir/Ruzasvir FDC

See AVIR's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

AVIR catalysts and pipeline →

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z